Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Bayer

Status: Completed

Conditions: Choroidal Neovascularization

Treatments: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Study type: Observational

Funder types: Industry

Identifiers

NCT02260687

17416

EY1414JP (Other Identifier)

Details and patient eligibility

About

The objectives of this study are to investigate the safety and effectiveness of EYLEA.

Full description

This is a prospective, non-interventional, multi center post-authorization safety study that includes patients with a diagnosis of myopic choroidal neovascularization. The investigator will have made the choice of treatment (EYLEA) as well as the decision to use EYLEA according the Japanese Package Insert prior to enrolling the patient in this study.

The observation period for each patient starts when therapy with EYLEA is initiated. The enrollment period is 2 years. Patients will be followed for a time period of 1 years or until it is no longer possible (e.g. lost to follow-up within the 1 year ). In total, 300 patients will be recruited.

For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visits and final visit, either by routine clinical visits (as per investigators routine practice) .

Enrollment: 353 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who start EYLEA treatment for mCNV(myopic choroidal neovascularization).

Exclusion criteria

• Patients who have already received EYLEA treatment.

Trial design

353 participants in 1 patient group

Group 1

Description:

Decision of treatment is made by attending investigator according to the Japanese Package Insert

Treatment:

Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)